Advanced Cell Technology, Inc. (ACTC) recently appeared in the 'Christmas and New Year Special' issue of New Scientist. Advanced Cell Technology's iPS cell-driven human platelet program has been named as one of the "10 Ideas That Will Shape the Year," by the magazine. New Scientist is widely considered to be one of the most influential science and technology news magazines in the world.
"Human iPS cells are a game-changer in medicine," said Robert Lanza, M.D., chief scientific officer of Advanced Cell Technology. "They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction…We hope to initiate the first clinical trial using these promising cells in 2013."
Advanced Cell Technology, Inc. has gained nearly 44% so far in the month of January.